|
gptkbp:instanceOf
|
gptkb:drug
GLP-1 receptor agonist
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BJ05
|
|
gptkbp:brand
|
gptkb:Trulicity
|
|
gptkbp:CASNumber
|
gptkb:923950-08-7
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:effect
|
weight loss
slows gastric emptying
decreases glucagon secretion
increases insulin secretion
reduction in HbA1c
|
|
gptkbp:eliminatedIn
|
proteolytic degradation
|
|
gptkbp:firstApprovalRegion
|
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
once weekly
|
|
gptkbp:halfLife
|
5 days
|
|
gptkbp:hasMolecularFormula
|
C4029H6207N1073O1262S32
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dulaglutide
|
|
gptkbp:indication
|
improving glycemic control in adults with type 2 diabetes
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonism
|
|
gptkbp:notRecommendedFor
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:patent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
children (in some regions)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:proteinSequenceType
|
recombinant
|
|
gptkbp:riskFactor
|
pancreatitis
hypoglycemia (when used with insulin or sulfonylureas)
thyroid C-cell tumors (in rodents)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
decreased appetite
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Trulicity
gptkb:GLP-1_receptor_agonists
|
|
gptkbp:bfsLayer
|
6
|